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Abstract
Background
Neurological outcomes of preterm infants with post-hemorrhagic hydrocephalus (PHH) re-
main among the worst in infancy, yet there remain few instruments to inform the treatment
of PHH. We previously observed PHH-associated elevations in cerebrospinal fluid (CSF)
amyloid precursor protein (APP), neural cell adhesion molecule-L1 (L1CAM), neural cell ad-
hesion molecule-1 (NCAM-1), and other protein mediators of neurodevelopment.
Objective
The objective of this study was to examine the association of CSF APP, L1CAM, and
NCAM-1 with ventricular size as an early step toward developing CSF markers of PHH.
Methods
CSF levels of APP, L1CAM, NCAM-1, and total protein (TP) were measured in 12 preterm
infants undergoing PHH treatment. Ventricular size was determined using cranial ultra-
sounds. The relationships between CSF APP, L1CAM, and NCAM-1, occipitofrontal circum-
ference (OFC), volume of CSF removed, and ventricular size were examined using
correlation and regression analyses.
Results
CSF levels of APP, L1CAM, and NCAM-1 but not TP paralleled treatment-related changes
in ventricular size. CSF APP demonstrated the strongest association with ventricular size,
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estimated by frontal-occipital horn ratio (FOR) (Pearson R = 0.76, p = 0.004), followed by
NCAM-1 (R = 0.66, p = 0.02) and L1CAM (R = 0.57,p = 0.055). TP was not correlated with
FOR (R = 0.02, p = 0.95).
Conclusions
Herein, we report the novel observation that CSF APP shows a robust association with ven-
tricular size in preterm infants treated for PHH. The results from this study suggest that CSF
APP and related proteins at once hold promise as biomarkers of PHH and provide insight
into the neurological consequences of PHH in the preterm infant.
Introduction
Intraventricular hemorrhage (IVH) is the most common, severe neurological complication of
preterm birth, occurring in roughly 25% of very low birth weight infants[1]. Post-hemorrhagic
hydrocephalus (PHH) occurs in up to one half of those with IVH [2] and is associated with a
3–4 fold increase in the risk of cognitive and psychomotor disability [3]. Infants with PHH
who require ventriculoperitoneal shunts (VPS) suffer the worst neurological outcomes, howev-
er, with neurodevelopmental impairments observed in>85% of extremely low birth weight in-
fants and cerebral palsy in nearly 70%[4].
Despite the profound morbidity associated with PHH, there remain few clinical, radio-
graphic, or laboratory parameters to guide treatment for PHH. Physical signs such as occipito-
frontal circumference (OFC, or head circumference), splaying of the cranial sutures, and
tenseness of the anterior fontanel are imprecise measures, and changes in vital signs such as
apnea or bradycardia occur only late in the disease course. Imaging-based measures of ventric-
ular size are frequently used for individualized treatment; yet ventricular size and/or morphol-
ogy may be affected by IVH, hypoxia-ischemia, white matter injury, and impaired brain
development—all of which are common among preterm infants[5]. Thus, there is a need to de-
velop new tools to complement ventricular measures and inform the treatment of PHH.
Using tandem multi-affinity immunodepletion quantitative nano-LC-MS proteomics, we
previously observed alterations in the abundance of key protein mediators of neurodevelop-
ment in the CSF of a different group of infants with PHH [6] prior to ventricular decompres-
sion. A cohort of these proteins, including amyloid precursor protein (APP), neural cell
adhesion molecule-L1 (L1CAM), and neural cell adhesion molecule-1 (NCAM-1), returned to
control levels after neurosurgical decompression was initiated [6]. APP has been shown to play
a role in synapse formation and repair, and neural plasticity [7,8]. Cleavage of APP may lead to
amyloid beta, which is the primary component of amyloid plaques frequently found in the
brains of patients with Alzheimer’s Disease [9–11]. L1CAM is a cell adhesion molecule that
generates transmembrane signals via tyrosine kinase receptors [12–15] and plays multiple roles
through development, such as neuronal migration, axonal growth, and synaptogenesis [15–
17]. Mutations in L1CAM have been linked to MASA syndrome, X-linked hydrocephalus, and
CRASH syndrome [18–22]. NCAM-1 is a transmembrane protein critical for cell migration,
cell survival, axonal guidance, and synaptic targeting and plasticity associated with cognitive
function [23–27]. In the current study, we measured serial CSF APP, L1CAM, and NCAM-1
concentrations in prematurely born infants throughout the interval when neurosurgical treat-
ment of PHH was carried out; specifically, we examined the relationship of CSF APP, L1CAM,
and NCAM-1 to ventricular size, total CSF protein, occipitofrontal circumference (OFC), and
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volume of CSF removed as part of clinical PHH treatment. Herein, we report the novel obser-
vation that CSF levels of APP are associated with ventricular size and may hold promise as a
candidate biomarker of PHH but also provide insight into the neurological sequelae of PHH.
Materials and Methods
Ethics Statement
Approval from the Washington University Human Research Protection Office (WU-HRPO)
was acquired prior to initiation of this study. Informed consent was obtained from subjects’
parent(s) or guardian(s) in all cases. As enrollment, consent, and/or sample acquisition were
frequently performed while the mother was receiving medical care at another facility or was
unable to travel to St. Louis Children’s Hospital, and as the study posed no more than minimal
risk to participants, verbal consent was deemed sufficient by the WU-HRPO (#201101887). In
the case of control subjects, written informed consent was obtained (WU-HRPO #201107082,
202013004). Consent, verbal or written, was documented in a regulatory binder for each
participant.
Research Subjects
As part of routine clinical care, all preterm infants34 weeks estimated post-menstrual age
(PMA) admitted to the St. Louis Children’s Hospital Neonatal Intensive Care Unit (NICU)
underwent routine head ultrasound (US) examinations between 0–5 days of age to screen for
IVH. Those found to have IVH then had weekly ultrasounds to monitor for PHH, and their OFC
was recorded daily. Infants who demonstrated a frontal-occipital horn ratio (FOR[28])0.55
and progressive increase in OFC, full fontanel (palpated above the level of surrounding bone),
and splaying of the sagittal suture2 mm in the mid-parietal region[29] underwent implanta-
tion of a ventricular reservoir (RES) to treat PHH. Once a RES was implanted, semi-quantitative
assessment of ventricular size and FOR (measured on head US performed 1–2 times/week), com-
bined with clinical parameters (OFC, fontanel tenseness, and suture splaying), were used to direct
the timing, frequency, and volume (typically 10–20 ml/kg per RES tap) of CSF removal for ven-
tricular decompression. At term-equivalent age (TEA, 370/7–416/7 weeks PMA), the requirement
for continued CSF removal was assessed, and a determination was made if the infant required a
permanent ventriculoperitoneal shunt (VPS).
The current study spanned 2.5yrs, during which time 25 infants underwent implantation of
a RES for PHH. Consent, verbal or written (see Ethics Statement above), was obtained in all
cases; however, only the 12 subjects included herein had5 ‘paired’ CSF samples and ultra-
sound examinations, where both the CSF sample and the ultrasound were acquired within a 24
window, an a priori criterion for enrollment in the current study. Eleven of the 12 subjects re-
quired a VPS; the remaining subject was transitioned to palliative care status due to cardiopul-
monary disease and expired prior to TEA. In those who underwent VPS, the final CSF sample
was obtained at the time of shunt implantation. None of the subjects enrolled in the study de-
veloped CSF, RES, or VPS infections. In order to account for differences in clinical risk severity
uniformly across the cohort, subjects were scored using the Clinical Risk Index for Babies II
(CRIB II)[30] taking into account PMA, sex, birthweight, and base excess. As temperature at
admission has been shown to be heavily influenced by patient care itself, subject clinical risk
index scores were reported using the CRIB II-T system [31]. Length of ventilation (LOV) was
also recorded as a second established metric of severity of illness in preterm neonates [32].
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Ultrasound Measurements of Ventricular Size
Cranial ultrasound examinations (US) examinations were obtained in infants with PHH at
least 1–2 times per week using a Zonarez.one UltraSmartCart diagnostic ultrasound system
(Mountain View, CA). Ventricular size was measured on each US using two previously re-
ported methods: ventricular index (VI; while bilateral, the larger of the two VI values was used)
[33] and frontal-occipital horn ratio (FOR)[28]. No US was performed beyond what was re-
quired for clinical purposes. As the intent of this study was to evaluate the association between
CSF proteins and ventricular size, only those US obtained within 24 hours of a CSF sample
were used for analysis.
Cerebrospinal Fluid Collection
CSF samples were obtained either directly from the operating room at the time of initial ven-
tricular cannulation (during reservoir implantation) or at the NICU bedside at the time of per-
cutaneous ventricular or RES taps. Final CSF samples were collected from the operating room
during VPS surgery. In all cases, CSF was acquired under sterile conditions and only as clinical-
ly indicated. Once acquired from the operating room or NICU, each CSF sample was trans-
ported to the Washington University Neonatal CSF Repository on ice and then centrifuged at
2500 rpm for 6 minutes. The supernatant was then aliquotted into microcentrifuge tubes
(500μl) and stored at -80°C until experimental analysis.
Plasma Collection
Cord blood was collected at term delivery from healthy newborn infants (in evacuated tubes
with anticoagulant), plasma separated within 2 hours, aliquotted and stored at -80°C
until analysis.
APP, L1CAM, and NCAM-1 Concentrations
Enzyme-Linked ImmunoSorbent Assays (ELISAs) were used to examine the CSF concentra-
tions of APP, L1CAM, and NCAM-1 throughout the PHH treatment interval. Sandwich Duo-
Set ELISA development systems (R&D Systems, catalog #DY-850 and DY-2408, Minneapolis,
MN) were used to measure APP and NCAM-1, as previously described [6]. Briefly, high-bind-
ing polystyrene microplates (Costar, Corning Life Sciences, INC., Lowell, MA) were coated
with mouse monoclonal anti-human APP or NCAM-1 primary antibody (4μg/mL and 2μg/mL
respectively). The plate was then blocked for an hour in 1% BSA. The CSF samples and standards
were incubated and then biotinylated goat anti-human APP or NCAM-1 secondary antibody
was added (300ng/mL and 200ng/mL respectively) followed by a streptavidin-HRP reagent.
After, the working stabilized hydrogen peroxide solution and stabilized tetramethylbenzidine
were loaded and incubated prior to the addition of sulfuric acid. L1CAM concentrations were
measured using a commercially available ELISA kit (DRG, catalog #EIA5074, Mountainside, NJ)
following the manufacturers protocol, also as previously described[6]. ELISAs were run in dupli-
cate, and the 96-well plates were read at 450nm on a Versamax microplate reader (Molecular De-
vices, Sunnyvale, CA). Actual APP, L1CAM, and NCAM-1 concentrations were determined
using a four parameter logistic standard curve as detailed by the manufacturers.
Total Protein Measurements
The Pierce Bicinchoninic Acid (BCA) protein assay kit (Thermo Scientific, Waltham, MA) was
used to determine the total concentration of protein in each CSF sample. Briefly, 25μl of CSF
and BSA standards were placed into the microplate wells (in duplicates); 200μl of the working
CSF APP Association with Ventricular Size in Premature Infants PHH
PLOSONE | DOI:10.1371/journal.pone.0115045 March 4, 2015 4 / 14
reagent was then added and the plate was incubated for 30min at 37°C. The plate was cooled to
room temperature and the absorbance was measured at 562nm on a plate reader. Total protein
concentrations were determined using a four parameter logistic standard curve.
Statistical Analysis
Data were expressed using mean ± standard deviation. Associations between continuous fac-
tors were assessed using the Pearson correlation coefficient. Rates of linear change over time
for markers and other measures were calculated using standard linear regression with the
marker/factor as outcome and timepoint as predictor. All data analyses were performed using
SAS 9.2.
Results
Patient Characteristics and PHH Treatment
Twelve prematurely born subjects (7 male, 5 female) with gestational age of 25.7±2.5 weeks
and birthweight of 865±361 grams were included. Characteristics of the cohort are shown in
Table 1. IVH was diagnosed prior to 31 weeks PMA (26.3±2.4 weeks) in all patients. RES and
VPS implantation were performed at 30±4 weeks (range 25–38) and 38±2 weeks (range 34.6–
40.9), respectively. The mean frequency for CSF removal and mean volume of CSF withdrawn
per procedure were 3±2 times/week and 13.9±4.9ml, respectively.
Cerebrospinal Fluid Protein and APP, L1CAM, and NCAM-1
Measurements
Variability was observed in the total protein (TP) in the CSF of the 12 PHH subjects, both in
terms of absolute levels and dynamic trends in concentration (increases/decreases) throughout
the PHH treatment interval (Fig. 1). Initial TP level was not associated with CRIB II-T (R =
0.24, p = 0.45) or LOV (R = -0.02, p = 0.96), proxies for critical illness in preterm infants, or
with length of time from IVH diagnosis to acquisition of the CSF sample (R = 0.03, p = 0.91).
Trends in TP tracked independently of changes in measured APP (R = -0.13, p = 0.69) and
Table 1. Characteristics of the 12 subjects with post-hemorrhagic hydrocephalus enrolled in the study.
Subject
Number
Race Sex Birth
weight
(g)
Birth
PMA
(wks)
CRIBII-
T
# of
US
# of CSF
samples
Average CSF
removed (ml)
IVH Dx
EGA
(wks)
Reservoir
Surgery EGA
(wks)
Shunt
Surgery EGA
(wks)
1 Black F 620 24 4/7 13 6 10 12.63 24 5/7 27 6/7 37 6/7
2 Caucasian M 650 25 5/7 13 4 6 15.00 28 2/7 37 5/7 40 5/7
3 Black M 740 24 3/7 14 23 46 11.88 24 5/7 28 4/7 37 3/7
4 Black F 740 24 14 7 11 13.63 24 2/7 27 6/7 34 5/7
5 Caucasian M 835 29 10 9 17 13.70 29 31 4/7 40 6/7
6 Caucasian M 850 25 2/7 12 14 24 18.31 25 3/7 28 40
7 Asian M 700 24 15 15 57 15.08 25 6/7 29 2/7 39 1/7
8 Black M 750 24 14 23 53 9.01 24 2/7 27 37 4/7
9 Caucasian F 730 23 6/7 13 6 12 8.82 24 1/7 28 4/7 N/A
10 Black F 610 23 1/7 14 12 26 6.67 24 3/7 25 37
11 Caucasian F 1300 29 4/7 3 14 34 17.80 29 5/7 31 2/7 36 4/7
12 Caucasian M 1854 30 4/7 3 5 13 25.25 30 5/7 36 3/7 40 3/7
doi:10.1371/journal.pone.0115045.t001
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showed marginal correlations with CSF L1CAM (R = -0.34, p = 0.28) and NCAM-1 (R = -0.45,
p = 0.14), respectively. Thus, in order to facilitate across-subject analyses, the CSF levels of
these proteins were normalized by TP elsewhere in this study, except where noted.
Cerebrospinal Fluid APP, L1CAM, and NCAM-1 Levels, and Ventricular
Size Metrics
In order to evaluate the relationship between candidate CSF biomarkers and ventricular size,
two commonly referenced ultrasound-based ventricular size parameters were assessed for
strength of association with CSF APP, L1CAM, and NCAM-1 levels. Specifically, ventricular
index (VI, measured bilaterally, the larger of the two was chosen for analysis) and FOR were
analyzed. FOR, which is ratiometric and takes into account the bilateral frontal and occipital
horns of the lateral ventricles and the brain size, consistently showed a more robust relation-
ship to normalized CSF levels of APP, L1CAM, and NCAM-1 than VI (Table 2). Thus, FOR
was selected as the primary ventricular measurement to report the association of these candi-
date CSF proteins to ventricular size. Of note, CSF TP alone did not demonstrate an apprecia-
ble correlation with FOR (R = 0.02, p = 0.95).
Cerebrospinal Fluid APP, L1CAM, and NCAM-1, and Ventricular Size
throughout the PHH Treatment Period
As detailed above, CSF was removed via RES taps as clinically indicated for the treatment of
each infant. To evaluate the relationship between CSF APP, L1CAM, and NCAM-1 levels and
Fig 1. Total protein. Total protein measurements (μg/ml) for all 12 PHH subjects analyzed throughout the
duration of the study.
doi:10.1371/journal.pone.0115045.g001
Table 2. The Pearson Correlation Coefﬁcients (and p-value) for normalized proteins and their
correlation with the ventricular size metrics Ventricular Index (VI) and Frontal-Occipital Horn Ratio
(FOR).
Protein* VI FOR
APP 0.58 (0.047) 0.76 (0.004)
L1CAM 0.51 (0.087) 0.57 (0.055)
NCAM-1 0.57 (0.051) 0.66 (0.019)
* All levels normalized by total protein.
doi:10.1371/journal.pone.0115045.t002
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ventricular size, the levels of each protein were measured in CSF samples obtained within 24h
of each cranial US. Fig. 2 shows the relationship between CSF APP levels and FOR for two typi-
cal subjects (data for all other subjects are included in S1–S7 Figs.). Fig. 2A includes TP and ab-
solute APP values, and Fig. 2B shows APP levels normalized by TP. Actual clinical ultrasound
images are provided in the insets for reference. A robust correlation was observed between CSF
APP and FOR, with CSF APP tracking ventricular size closely throughout the PHH treatment
interval.
Common neurosurgical practice is to taper or stop RES taps prior to VPS implantation in
order to: 1) assess the need for permanent VPS after temporizing PHH treatment with RES
taps (i.e. to evaluate each subject’s ability to regain the capacity to absorb CSF); and 2) facilitate
the function of the VPS, if one is required (to “prime” the VPS). As shown in Fig. 2, CSF APP
detected the expected increase in ventricular size as RES taps were stopped. Similar observa-
tions were made with CSF L1CAM (Fig. 3A) and CSF NCAM-1 (Fig. 3B).
In order to quantitate the strength of association between normalized CSF APP, L1CAM,
and NCAM-1 with FOR, the rate of linear change in each CSF protein was plotted against the
rate of linear change in FOR for each subject (Fig. 4A-C). While there was some variability in
the rate of linear change for each CSF protein among subjects, likely due to inherent variation
in the treatment of individual subjects, a strong correlation was observed for change in FOR
with changes in CSF APP (R = 0.76, p = 0.004); a moderately strong correlation was also ob-
served for CSF NCAM-1(R = 0.66,p = 0.02), and a trend toward correlation was seen with CSF
L1CAM(R = 0.57,p = 0.055) (Table 2). Of note, there was no relationship between FOR and TP
(R = 0.02, p = 0.95), and the associations between FOR and OFC (R = 0.36, p = 0.25), and vol-
ume of CSF removed (R = -0.13, p = 0.70) were very weak.
Fig 2. FOR and APP levels. A.FORmeasurements (red left y-axis) and absolute APP concentrations (blue
right y-axis) and total protein (black right y-axis) plotted versus relative time of reservoir surgery in selected
timepoints of patients #7 (left) and #8 (right). Each FOR data point is accompanied by an US image for the
selected patient at that particular timepoint. The image shown is a coronal slice taken at the foramen of
Monro.B. FORmeasurements (left y-axis) and normalized APP levels (right y-axis) plotted versus relative
time of reservoir surgery in selected timepoints of patients #7 (left) and #8 (right).
doi:10.1371/journal.pone.0115045.g002
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Initial Peak APP, L1CAM, and NCAM-1 Levels, and Ventricular Size
In addition to examining the relationship between APP, L1CAM, and NCAM-1 levels and ven-
tricular size in individual infants in repeated CSF samples over time, we also examined the CSF
levels of these proteins across all subjects at the time of the initial CSF sample (at the start of
temporizing PHH treatment, i.e. previously untreated PHH). After normalizing for TP, APP,
L1CAM, and NCAM-1 levels, measured in CSF obtained at the time of initiation of PHH treat-
ment, were not consistently associated with FOR (R = -0.11, -0.14, and 0.17, respectively). Sim-
ilarly, no clear association was observed between initial APP, L1CAM, or NCAM-1 levels and
length of time (in days) after IVH diagnosis (R = 0.18, -0.23, and 0.09 respectively).
Plasma Levels of APP, L1CAM, and NCAM-1
As IVH is a critical factor in the pathogenesis of PHH, it is important to exclude blood itself as
a major potential source for CSF APP, L1CAM, and NCAM-1. To this end, we examined the
concentration of APP, L1CAM, and NCAM-1 in the plasma of age-matched infants without
PHH or other known neurological injury. In this cohort, plasma APP = 126±51ng/ml, plasma
L1CAM = 13±5ng/ml, and plasma NCAM-1 = 442±102ng/ml. For comparison, the concentra-
tions of APP, L1CAM, and NCAM-1 measured in the initial CSF samples obtained in the 12
PHH subjects included in this study were 3194±1952ng/ml, 771±472ng/ml, and 483±183ng/ml,
respectively. In contrast to NCAM-1 (p = 0.53), APP and L1CAM demonstrated significantly
Fig 3. FOR, L1CAM, and NCAM-1 levels. A.FORmeasurements (red left y-axis) and absolute L1CAM concentrations (blue right y-axis) plotted versus
relative time of reservoir surgery in selected timepoints of patients #7 (left) and #8 (right). B. FORmeasurements (left y-axis) and absolute NCAM-1
concentrations plotted versus relative time of reservoir surgery in selected timepoints of patients #7 (left) and #8 (right).
doi:10.1371/journal.pone.0115045.g003
CSF APP Association with Ventricular Size in Premature Infants PHH
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higher levels in PHH CSF than in the plasma of age-matched infants without PHH or other neu-
rological injury (p = 0.0003 and p = 0.001, respectively).
Discussion
The current study was directed at evaluating the relationship between CSF levels of APP,
L1CAM, and NCAM-1, with ventricular size. Our previous work suggested that these and
other specific protein mediators of neurodevelopment exhibited increased levels in the CSF of
infants with untreated PHH, but they decreased to control levels after the initiation of neuro-
surgical treatment[6]. Using tandem multi-affinity proteomics, we previously identified a co-
hort of CSF proteins, including APP, L1CAM, and NCAM-1, that demonstrated marked
differences between PHH and control. In the current study, we observed that the CSF levels of
APP paralleled changes in ventricular size throughout the clinical PHH treatment interval. We
also noted a trend toward moderate association between L1CAM and ventricular size which
did not achieve statistical significance likely related to the small sample size. NCAM-1 was cor-
related with ventricular size, though to a lesser extent than APP, but was not enriched in PHH
CSF. Taken together, our results suggest that APP, and possibly other related proteins, hold
promise as biomarkers of PHH, potentially complementing physical parameters and existing
image-based measures of ventricular size in the treatment of this condition.
Fig 4. Correlation of FORwith normalized proteins. A linear regression analysis showing the correlation of normalized APP (A), normalized L1CAM (B),
and normalized NCAM-1 (C) with FORmeasurements for all 12 subjects used.
doi:10.1371/journal.pone.0115045.g004
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The finding that CSF proteins, particularly APP or others with involvement in neurodeve-
lopmental processes may be associated with ventricular size lends support to the notion that
these proteins may represent candidate markers of PHH and its associated neurological disabil-
ity. At present, crude physical findings and semi-quantitative parameters of ventricular size,
often obtained in the setting of abnormal ventricular morphology (resulting from adjacent
white matter injury/loss, porencephaly, or other causes) are used to direct treatment for PHH.
Thus, there is significant momentum to develop novel candidate PHH biomarker to comple-
ment existing physical and image-based parameters to aid in the diagnosis and management of
PHH.
The mechanism by which PHH results in increases in the CSF levels of APP, L1CAM,
NCAM-1, and perhaps other proteins remains unclear. While it would seem possible that the
initial IVH and blood products that remain in the CSF could result in elevations in these CSF
proteins (or total CSF protein more generally), the data reported herein do not support this ex-
planation. Using age-matched control plasma samples, we found that APP and L1CAM levels
are 25 fold and 59 fold (respectively) higher in PHH CSF than control plasma, making it un-
likely that blood products alone could be responsible (the notable exception was NCAM-1,
where there was no difference between control plasma and PHH CSF).
In the current study, CSF APP tracked ventricular size closely, even demonstrating increases
when ventricular size increased. These findings also argue against blood products as the origin
of these CSF protein levels; rather, they raise the possibility that secondary axonal and/or neu-
ronal injury may be contributing to elevations. Amyloid precursor protein is known to be re-
leased by axonal injury or stretch[34]; thus it is plausible that ventricular distention in
hydrocephalus, and axonal stretch as a consequence, could represent the origin of the observed
changes in CSF APP.
In the setting of hydrocephalus, increased ventricular size may be associated with increased
intracranial pressure (ICP). While it is of interest to determine the relationship of these candi-
dates CSF biomarkers to ICP, this presents several challenges in the study of human preterm
infants with PHH. First, the validity of ICP measurements in preterm infants with patent crani-
al sutures is unclear, since the open sutures likely attenuate increases in ICP. For this reason
OFC is often used as a surrogate for ICP, but this measurement is subject to measurement
error under the best of conditions. Further, treatment of PHH with RES is dominated by inter-
mittent CSF removal, leading to fluctuations in ICP, rather than the more continuous CSF di-
version provided through ventriculo-subgaleal shunts or VPS; however, by their very nature
(risk of infection), routine CSF access is not practical with these devices. Further, ICP in the
preterm infant with PHHmay be affected by a number of other factors independent of CSF re-
moval, including IV sedation, anesthesia (particularly at surgery), and wide variations in venti-
lator support, all of which would be expected to influence ICP. Finally and most importantly,
bedside percutaneous RES taps are often accompanied by crying and movement by the infant,
which inevitably transiently increases ICP during the tap, complicating the use of traditional
manometers and the interpretation of their values. However, we were able to record ICP (mea-
sured as opening pressure on manometry after insertion of the needle into the RES) in two in-
fants with serial RES sampling. While preliminary, ICP and normalized APP did demonstrate
an association in these two infants (R = 0.59 and 0.57, respectively). Currently, we are investi-
gating CSF APP, L1CAM, and other proteins in hydrocephalus of varying etiologies that affect
older children and adolescents, where many of these issues will be mitigated, permitting a
clearer assessment of the relationship between candidate CSF markers, ICP, and ventricular
size. However, it is likely that animal models will ultimately be needed to fully resolve this
issue.
CSF APP Association with Ventricular Size in Premature Infants PHH
PLOSONE | DOI:10.1371/journal.pone.0115045 March 4, 2015 10 / 14
The findings of this study are subject to a number of limitations. The data were derived
from a small number of preterm infants (n = 12), with inherent variability in medical co-mor-
bidities and clinical care. In addition, 11 of the 12 subjects required a permanent VPS, while
the final subject expired from non-neurological causes before reaching TEA, the point at which
VPS is considered. Since only 70–80% of patients typically require VPS[35,36], it is possible
that our sample of 12 patients represents a biased sample; certainly, by excluding patients that
did not require serial CSF removal, the VPS rate in this study would be expected to be higher
than studies that report VPS rates for all infants treated for post-hemorrhagic ventricular dila-
tation. Alternatively, it could be argued that each subject, by requiring VPS, had confirmed
PHH, rather than simply post-hemorrhagic ventricular dilatation. Regardless, the findings re-
ported herein must be confirmed in a larger sample size. To this end, a multi-institutional
study of candidate CSF markers of PHH is currently underway through the Hydrocephalus
Clinical Research Network (HCRN). Finally, the scope of this study was limited to CSF APP,
L1CAM, and NCAM-1; as demonstrated previously[6], there are a number of important pro-
teins (e.g. amyloid isoforms, tau, others) to be assessed for association with ventricular size.
Conclusion
In the current study, we report the novel observation that the CSF level of APP is associated
with ventricular size in preterm infants undergoing treatment for PHH. The results from this
study suggest that specific CSF proteins, such as APP, when paired with physical parameters
and traditional imaging-based measures of ventricular size, may provide additional informa-
tion regarding disease status and therapeutic efficacy. Future work will be directed at evaluating
the role of CSF APP and related proteins as candidate markers of PHH and at investigating the
pathophysiological implications and developmental consequences of these CSF protein
changes.
Supporting Information
S1 Fig. Total CSF protein and FOR. Total CSF protein concentrations (μg/mL) (blue left y-
axis) and FOR measurements (red right y-axis) plotted versus relative time of reservoir surgery
in all timepoints used for all twelve subjects.
(TIF)
S2 Fig. CSF APP concentrations and FOR. CSF Amyloid Precursor Protein concentrations
(ng/mL) (blue left y-axis) and FOR measurements (red right y-axis) plotted versus relative
time of reservoir surgery in all timepoints used for all twelve subjects.
(TIF)
S3 Fig. CSF L1CAM concentrations and FOR. CSF L1CAM concentrations (ng/mL) (blue
left y-axis) and FOR measurements (red right y-axis) plotted versus relative time of reservoir
surgery in all timepoints used for all twelve subjects.
(TIF)
S4 Fig. CSF NCAM-1 concentrations and FOR. CSF NCAM-1 concentrations (ng/mL) (blue
left y-axis) and FOR measurements (red right y-axis) plotted versus relative time of reservoir
surgery in all timepoints used for all twelve subjects.
(TIF)
S5 Fig. Normalized CSF APP and FOR. Normalized CSF Amyloid Precursor Protein levels
(blue left y-axis) and FOR measurements (red right y-axis) plotted versus relative time of
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reservoir surgery in all timepoints used for all twelve subjects.
(TIF)
S6 Fig. Normalized CSF L1CAM and FOR. Normalized CSF L1CAM levels (blue left y-axis)
and FOR measurements (red right y-axis) plotted versus relative time of reservoir surgery in all
timepoints used for all twelve subjects.
(TIF)
S7 Fig. Normalized CSF NCAM-1 and FOR. Normalized CSF NCAM-1 levels (blue left y-
axis) and FOR measurements (red right y-axis) plotted versus relative time of reservoir surgery
in all timepoints used for all twelve subjects.
(TIF)
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